Nurix Therapeutics, Inc. (NRIX)
- Previous Close
13.75 - Open
13.29 - Bid 12.34 x 200
- Ask 12.39 x 200
- Day's Range
12.27 - 13.34 - 52 Week Range
4.22 - 18.12 - Volume
942,879 - Avg. Volume
1,022,869 - Market Cap (intraday)
754.794M - Beta (5Y Monthly) 2.06
- PE Ratio (TTM)
-- - EPS (TTM)
-2.66 - Earnings Date Jul 11, 2024 - Jul 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.60
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
www.nurixtx.comRecent News: NRIX
Performance Overview: NRIX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NRIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRIX
Valuation Measures
Market Cap
754.79M
Enterprise Value
539.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.34
Price/Book (mrq)
4.47
Enterprise Value/Revenue
6.68
Enterprise Value/EBITDA
-3.78
Financial Highlights
Profitability and Income Statement
Profit Margin
-178.93%
Return on Assets (ttm)
-28.80%
Return on Equity (ttm)
-65.37%
Revenue (ttm)
80.89M
Net Income Avi to Common (ttm)
-144.73M
Diluted EPS (ttm)
-2.66
Balance Sheet and Cash Flow
Total Cash (mrq)
243.99M
Total Debt/Equity (mrq)
17.28%
Levered Free Cash Flow (ttm)
-34.76M